HD2 is a potent (IC50 = 2.96 nM) inhibitor of DCN1, an important co-E3 ligase of neddylation. Displays favorable pharmacokinetics and low toxicity (including no hepatotoxicity). Selective against other DCN family members as well as ACE. HD2 reduced the migration and proliferation of Ang II-treated cardiac fibroblasts. Active in an isoproterenol-induced pathological cardiac remodeling and fibrosis mouse model. HD2 is a promising new therapeutic option for treatment of cardiac remodeling and fibrosis.
* VAT and and shipping costs not included. Errors and price changes excepted
